Chase Investment Counsel Corp Has $1.10 Million Holdings in Merck & Co., Inc. (NYSE:MRK)

Chase Investment Counsel Corp boosted its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 3.2% during the 1st quarter, Holdings Channel reports. The institutional investor owned 8,360 shares of the company’s stock after purchasing an additional 259 shares during the quarter. Chase Investment Counsel Corp’s holdings in Merck & Co., Inc. were worth $1,103,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Hudock Inc. lifted its holdings in Merck & Co., Inc. by 10.5% during the 1st quarter. Hudock Inc. now owns 26,764 shares of the company’s stock worth $3,532,000 after buying an additional 2,538 shares in the last quarter. Summit Financial Wealth Advisors LLC lifted its holdings in Merck & Co., Inc. by 2.2% during the 1st quarter. Summit Financial Wealth Advisors LLC now owns 73,985 shares of the company’s stock worth $9,762,000 after buying an additional 1,605 shares in the last quarter. Magnolia Capital Advisors LLC lifted its holdings in Merck & Co., Inc. by 10.6% during the 1st quarter. Magnolia Capital Advisors LLC now owns 17,640 shares of the company’s stock worth $2,219,000 after buying an additional 1,685 shares in the last quarter. FinTrust Capital Advisors LLC lifted its holdings in Merck & Co., Inc. by 11.7% during the 1st quarter. FinTrust Capital Advisors LLC now owns 9,712 shares of the company’s stock worth $1,281,000 after buying an additional 1,019 shares in the last quarter. Finally, Wright Investors Service Inc. lifted its holdings in Merck & Co., Inc. by 3.0% during the 1st quarter. Wright Investors Service Inc. now owns 39,022 shares of the company’s stock worth $5,149,000 after buying an additional 1,120 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MRK. Berenberg Bank increased their price target on Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Merck & Co., Inc. in a research note on Tuesday, June 18th. Argus raised Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, June 5th. Truist Financial increased their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Finally, Wells Fargo & Company increased their price target on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $133.00.

View Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Trading Up 0.2 %

Shares of NYSE:MRK opened at $126.08 on Wednesday. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $134.63. The company has a market capitalization of $319.34 billion, a P/E ratio of 140.09, a price-to-earnings-growth ratio of 2.43 and a beta of 0.38. The company has a 50-day simple moving average of $128.99 and a 200 day simple moving average of $125.39. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. During the same period last year, the business posted $1.40 EPS. Merck & Co., Inc.’s revenue was up 8.9% on a year-over-year basis. Sell-side analysts forecast that Merck & Co., Inc. will post 8.62 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, July 8th. Shareholders of record on Monday, June 17th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Monday, June 17th. This represents a $3.08 annualized dividend and a yield of 2.44%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 342.22%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.